Eikon remains in megaround mode with $350M series D to fund cancer trials
Eikon Therapeutics is no stranger to eye-catching funding rounds, and the cancer-focused biotech has continued this trend with a $350.7 million series D to fuel its various clinical trials.
Eikon Therapeutics is no stranger to eye-catching funding rounds, and the cancer-focused biotech has continued this trend with a $350.7 million series D to fuel its various clinical trials.
